Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Most Popular

Check out the most popular stories and multimedia features across the site right now

Biotech

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

By Adam Feuerstein

Biotech

The Biotech Devil’s Dictionary: Your guide to the inanities of industry jargon

By Damian Garde

advertisement

Hospitals

A $200 million gift promotes alternative therapies at a California medical school — and critics recoil

By Usha Lee McFarling

advertisement

A STAT Investigation

IBM pitched its Watson supercomputer as a revolution in cancer care. It’s nowhere close

By Casey Ross and Ike Swetlitz

Politics

In Congress, a doctor becomes a cancer patient — and preaches candor

By Erin Mershon

Health

A study, with some limitations, sees link between youth football and emotional issues in adulthood

By Bob Tedeschi

The Pharmalot View

This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge

By Ed Silverman

advertisement

Heavyweights

Did he really just tweet that? Dr. Vinay Prasad takes on Big Pharma, Big Medicine, and his own colleagues — with glee

By Meghana Keshavan

advertisement

Health

Early medical photos, long hidden, now destined for the high bidders

By Bob Tedeschi

Health

‘Every time it’s a battle’: In excruciating pain, sickle cell patients are shunted aside

By Sharon Begley

Biotech

A biotech scorecard: Taking stock of the industry’s make-or-break September

By Damian Garde

Pharmalot

Brand-name drug prices are still rising, just not as fast as before

By Ed Silverman

Pharmalot

Dozens of states probe role of drug makers and distributors in the opioid crisis

By Ed Silverman

First Opinion

Some tax-exempt hospitals are lax at providing charity care and accountability

By Chuck Grassley

Business

Commercial launch of Portola’s new blood thinner could be threatened by new clinical guidelines

By Adam Feuerstein

Pharmalot

Some drugs that are heavily promoted to doctors may not be worth it

By Ed Silverman

Health

Why fentanyl is deadlier than heroin, in a single photo

By Allison Bond

Politics

Under GOP health care bill, states would struggle to hang onto Obamacare

By Erin Mershon

Health

Educational event or swag-fest? Addiction treatment companies chase business with flashy giveaways

By David Armstrong — STAT and Evan Allen — Boston Globe

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

Industry

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT

X